Recent years, increasing of immunotherapy for AML has appeared, such as antibody therapy [14] (targeting CD33, CD123, and several other antigens), redirected T cells [14, 15] (anti-CD19 CAR T cells, anti-CD33 CAR T cells, anti-CD123 CAR T cells, et al.), checkpoint inhibitors (targeting PD-1/PD-L1) [16]. This evidence concerns the gene CD33 and acute myeloid leukemia.